PD-1 Inhibitor Treatment Effective for Localized Mismatch Repair-Deficient CRC
FRIDAY, Jan. 13, 2023 -- For localized mismatch repair-deficient (dMMR) colorectal cancer (CRC), neoadjuvant programmed death-1 (PD-1) inhibitor treatment is effective, according to a study published online Jan. 11 in the Journal of the National...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | Colorectal Cancer | Gastroschisis Repair | Neoadjuvant Therapy | Pharmaceuticals | Study